Showing results (51-60 of 64) with videos related to
Sort By:
Pageof 7
Diabetes Care|May 20, 1999
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetesR Moses, R Slobodniuk, S Boyages, et al.Clinical Obesity|August 13, 2013
Trends in overweight and obesity over 22 years in a large adult population: the HUNT Study, NorwayK Midthjell, C M Y Lee, A Langhammer, et al.Diabetic Medicine : a Journal of the British Diabetic Association|June 24, 2004
Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetesS R Heller, S Colagiuri, S Vaaler, et al.Journal of Internal Medicine|February 27, 2008
The metabolic syndrome as a tool for predicting future diabetes: the AusDiab studyA J Cameron, D J Magliano, P Z Zimmet, et al.Journal of Paediatrics and Child Health|May 31, 2025
Population Incidence and Burden of Juvenile Idiopathic Arthritis on Australian Health System: Data Linkage StudyS J Lain, L Ivancic, J Chaitow, et al.Diabetic Medicine : a Journal of the British Diabetic Association|March 26, 2009
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)M Marre, J Shaw, M Brändle, et al.Internal Medicine Journal|May 7, 2015
Cost to government and society of chronic kidney disease stage 1-5: a national cohort studyM L R Wyld, C M Y Lee, X Zhuo, et al.Diabetologia|February 17, 2010
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) StudyA P Kengne, A Patel, S Colagiuri, et al.European Psychiatry : the Journal of the Association of European Psychiatrists|October 4, 2011
Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trialG-D Batty, Q Li, R Huxley, et al.International Journal of Obesity (2005)|August 30, 2012
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care--an international randomised controlled trialN R Fuller, S Colagiuri, D Schofield, et al.Pageof 7